MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Revvity Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

101.57 1.52

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

100.72

Max

101.63

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-53M

42M

Pardavimai

-65M

665M

P/E

Sektoriaus vid.

39.967

40.527

Pelnas, tenkantis vienai akcijai

1.01

Dividendų pajamingumas

0.29

Pelno marža

6.268

Darbuotojai

11,000

EBITDA

-50M

173M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+15.71% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.29%

2.40%

Kitas uždarbis

2025-07-28

Kitas dividendų mokėjimo data

2025-08-08

Kita Ex Dividend data

2025-07-18

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-2.6B

11B

Ankstesnė atidarymo kaina

100.05

Ankstesnė uždarymo kaina

101.57

Naujienos nuotaikos

By Acuity

31%

69%

71 / 375 reitingas Healthcare

Revvity Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-04 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-04 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-07-04 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-07-04 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-07-04 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-07-04 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-04 15:57; UTC

Rinkos pokalbiai

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

2025-07-04 15:49; UTC

Rinkos pokalbiai

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

2025-07-04 15:49; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

2025-07-04 15:49; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

2025-07-04 15:49; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Received All Required Authorizations

2025-07-04 15:48; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

2025-07-04 15:47; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: Agreement Was Announced on Dec. 19

2025-07-04 15:47; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

2025-07-04 15:46; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

2025-07-04 14:30; UTC

Įsigijimai, susijungimai, perėmimai

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

2025-07-04 13:53; UTC

Rinkos pokalbiai

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

2025-07-04 13:41; UTC

Rinkos pokalbiai

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

2025-07-04 13:41; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-07-04 13:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-04 12:37; UTC

Rinkos pokalbiai

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

2025-07-04 12:37; UTC

Rinkos pokalbiai

Fund Manager Roundup: U.S. Treasurys in Focus -2-

2025-07-04 12:30; UTC

Rinkos pokalbiai

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

2025-07-04 12:15; UTC

Rinkos pokalbiai

Targeted Tariffs Would Likely Support Dollar -- Market Talk

2025-07-04 12:13; UTC

Rinkos pokalbiai

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

2025-07-04 12:02; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-04 12:02; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

Akcijų palyginimas

Kainos pokytis

Revvity Inc Prognozė

Kainos tikslas

By TipRanks

15.71% į viršų

12 mėnesių prognozė

Vidutinis 117.23 USD  15.71%

Aukščiausias 135 USD

Žemiausias 100 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Revvity Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

14 ratings

9

Pirkti

5

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

71 / 375 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.